113 results
424B3
EVOK
Evoke Pharma Inc
14 Mar 24
Prospectus supplement
6:44pm
with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue … sphincter. Previously-approved drugs, such as cisapride and tegaserod, are no longer commercially available in the United States because of safety
8-K
EX-99.1
utlm226
14 Mar 24
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
4:00pm
8-K
EX-1.1
1b7x pw10e
9 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
5:15pm
424B4
x0xsse5e6rs82p
9 Feb 24
Prospectus supplement with pricing info
5:14pm
8-K
EX-99.1
88wo99wz w4yyszk
15 May 23
Evoke Pharma Reports First Quarter 2023 Financial Results
4:23pm